KR950700419A - 단량체 및 이량체 항체-단편 융합 단백질(monomeric and dimeric antibody-fragment fusion proteins) - Google Patents

단량체 및 이량체 항체-단편 융합 단백질(monomeric and dimeric antibody-fragment fusion proteins)

Info

Publication number
KR950700419A
KR950700419A KR1019940702517A KR19940702517A KR950700419A KR 950700419 A KR950700419 A KR 950700419A KR 1019940702517 A KR1019940702517 A KR 1019940702517A KR 19940702517 A KR19940702517 A KR 19940702517A KR 950700419 A KR950700419 A KR 950700419A
Authority
KR
South Korea
Prior art keywords
protein
fusion
fragment
peptide
antibody
Prior art date
Application number
KR1019940702517A
Other languages
English (en)
Other versions
KR100254759B1 (ko
Inventor
플뤼크툰 안드레아스
팍크 페터
Original Assignee
위르겐 오이만, 라인하르트 슈틀러
메르크 파텐트 게젤샤프트 미트 베쉬랭크터 하프퉁
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 위르겐 오이만, 라인하르트 슈틀러, 메르크 파텐트 게젤샤프트 미트 베쉬랭크터 하프퉁 filed Critical 위르겐 오이만, 라인하르트 슈틀러
Publication of KR950700419A publication Critical patent/KR950700419A/ko
Application granted granted Critical
Publication of KR100254759B1 publication Critical patent/KR100254759B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 항체의 Fv-단편을 포함하나 불변 항체 도메인을 이용하지 않는 새로운 부류의 항원 결합 분자를 제공한다. 또한 이들 분자는 다른 항체 단편 분자 또는 비-항체 단편 분자와 이량화되어 각각 이-또는 다-작용성 항체-단편 융합 단백질 및 소위 미니항체를 형성한다. 신규 융합 단백질은 진단 및 치료의학의 광범위한 분야에서 사용될 수 있다.

Description

단량체 및 이량체 항체-단편 융합 단백질(MONOMERIC AND DIMERIC ANTIBODY -FRAGMENT FUSION PROTEINS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1 도 scFv 단편을 함유하는 scFv-발현 벡터 pLISC-SE, 제 2 도 2시스트론 scFv-힌지-지퍼 발현 벡터 pACKxFyJ, 제 3 도 작용적 ELISA; OD280으로 측정한 친화성 정제 단백질의 농도(세로축)는 웰당 결합 부위의 몰 수(가로축)를 의미한다. ELISA 플레이트는 포스포콜린으로 피복되고 정제된 포스포콜린-특이적 미니항체-단백질이 결합되었으며 항-McPC603 항혈청으로 검출되었다. (a)다양한 미니항체의 비교, (b)ScFv 및 전체 IgA와 미니항체 scHLXc의 비교.

Claims (24)

  1. 비공유 상호작용에 이해 다른 펩티드와 이량체를 형성할 수 있는 펩티드 및 항체의 Fv-단편으로 필수적으로 구성되는 항체-단편 융합 단량체 단백질.
  2. 제 1 항에 있어서, 상기 Fv-단편이 단일 사슬 단편임을 특징으로 하는 단량체 단백질.
  3. 제 1 항 또는 제 2 항에 있어서, 상기 상호작용 펩트드가 10 내지 50개, 바람직하게는 10 내지 30개의 아미노산으로 구성됨을 특징으로 하는 단량체 단백질.
  4. 제 1 항 내지 제 3 항중 어느 한 항에 있어서, 상기 펩티드가 적어도 하나의 나선으로 구성됨을 특징으로 하는 단량체 단백질.
  5. 제 4 항에 있어서, 상기 나선 펩티드가 나선, 돌기 및 다른 나선으로 구성됨을 특징으로 하는 단량체 단백질.
  6. 제 4 랑에 있어서, 상기 펩티드가 매 7 번째 아미노산이 류신인 몇개의 반복 아미노산을 가지는 류신지퍼 분자를 포함함을 특징으로 하는 단량체 단백질.
  7. 제 4 항에 있어서, 상기 펩티드가 전하를 띤 잔기임을 특징으로 하는 단량체 단백질.
  8. 제 1 항 내지 제 7 항중 어느 한항에 있어서, 상기 결합 펩티드가 Fv-단편과 펩티드사이에 존재함을 특징으로 하는 단량체 단백질.
  9. 제 8 항에 있어서, 상기 결합 펩티드가 항체의 힌지 영역 서열 또는 그의 단편임을 특징으로 하는 단량체 단백질.
  10. Fv-단편, 상호작용 펩티드 및 필요하다면 결합 펩티드를 암호화하는 유전자를 하나의 발현 플라스미드를 클로닝시키고, 이 발현 플라스미드로 숙주 세포를 형질전환시키고, 자양액중에서 숙주 세포를 배양하고, 융합 단량체 단백질을 세포내에서 발현시키거나 또는 배지로 분비시킴을 특징으로 하는, 제 1 항 내지 제 9 항중 어느 한 항에 정의된 바와 같은 항체 융합 단량체 단백질의 제조방법.
  11. 제10항에 있어서, 상기 숙주 세포가 대장균임을 특징으로 하는 방법.
  12. 적어도 하나의 단량체 단위가 제 1 항내지 제 9 항중 어느 한 항에서 정의된 바와 같은 항체-단편 융합 단백질임을 특징으로 하는, 단량체 단위의 결합이 같거나 다른 펩티드의 비공유 상호 작용에 기초하는 두개의 융합 단량체 단백질로 필수적으로 구성되는 융합 이량체 단백질.
  13. 제12항에 있어서, 상기 상호작용 펩티드가 동일한 융합 이량체 단백질.
  14. 제12항 또는 제13항에 있어서, 상기 제 2 단량체 단위가 다른 특이성을 가지는, 제 1 항 내지 제 9 항에서 정의된 바와 같은 항체-단편 융합 단백질임을 특징으로 하는 이량체 단백질.
  15. 제12항 또는 제13항에 있어서, 상기 제 2 단량체가, 항체-단편(Fv)이 비-항체 단백질 또는 펩티드로 대체된 제 1 항 내지 제 9 항중 어느 한 항에서 정의된 바와 같은 융합 단백질임을 특징으로 하는 이량체 단백질.
  16. 제15항에 있어서, 상기 단백질 또는 펩티드가 독소, 펩티드 킬레이트화제, 금속 결합 단백질 또는 효소이거나, 또는 대응하는 특이적 결합 부위를 가짐을 특징으로 하는 이량체 단백질.
  17. 제15항에 있어서, 상기 단백질 또는 펩티드가 T-세포- 또는 T-세포 단편 특이적 결합 부위임을 특징으로 하는 이량체 단백질.
  18. 제12항 내지 제17항중 어느 한 항에 있어서, 상기 다른 단백질이 개재 펩티드의 하나 또는 둘다의 C-말단에 융합함을 특징으로 하는 이량체 단백질.
  19. 제18항에 있어서, 상기 융합 단백질이 독소, 펩티드 킬레이트화제, 금속 결합 단백질 또는 효소이거나, 또는 대응하는 특이적 결합 부위를 가지거나, 또는 T-세포(단편) 특이적 결합 부위를 가짐을 특징으로 하는 이량체 단백질.
  20. 완전한 융합 단량체 단백질 또는 그의 일부분을 암호화하는 유전자를 최소한 하나의 발현 플라스미드에 클로닝시키고, 이 발현 플라스미드(들)로 숙주 세포를 형질전환시켜 자양액중에서 배양하고, 완전한 융합 이량체 단백질을 세포내에서 발현시키거나 배지로 발현시키거나, 또는 융합 단량체 단백질을 별도로 발현시키고, 두개의 단량체 단위 사이의 비공유 결합을 배지 또는 실험관내에서 실시하고, 융합 단백질의 일부만이 클로닝될 경우에는 단백질 공학 단계를 부가적으로 실시함을 특징으로 하는, 제12항 내지 제19항중 어느 한 항에서 정의된 바와 같은 융합 이량체 단백질의 제조 방법.
  21. 제20항에 있어서, 제 1 융합 단량체 단백질을 암호화하는 유전자를 제 1 발현 플라스미드에 클로닝하고, 제 2 융합 단량체 단백질을 암호화하는 유전자를 제 2 발현 플라스미드에 클로닝함을 특징으로 하는 방법.
  22. 제20항에 있어서, 융합 이량체 단백질을 형성하는 단량체 단위사이의 비공유 결합을 실험관내에서 실시함을 특징으로 하는 방법.
  23. 제20항 내지 제22항중 어느 한 항에 있어서, 숙주 세포가 대장균임을 특징으로 하는 방법.
  24. (a)제 1 항 내지 제 8 항중 어느 한 항에서 정의된 바와 같은 항체-단편 융합 단량체 단백질 및 (b)(a)에서 정의된 바와 같은 제 2 융합 단량체 단백질을 포함하는 제12항 내지 제19항중 어느 한 항에서 정의된 바와 같은 항체-단편 융합 단백질(항체-단편은 같거나 다른 항원 특이성을 가지거나 또는 항체 단편 단위는 비-항체 단백질/펩티드로 대체된다)의 선별적인 이량체를 제조하기 위한 제조 킷트.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940702517A 1992-01-23 1993-01-15 단량체 및 이량체 항체-단편 융합 단백질 KR100254759B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP92101069.0 1992-01-23
DE92101069.0 1992-01-23
EP92101069 1992-01-23
PCT/EP1993/000082 WO1993015210A1 (en) 1992-01-23 1993-01-15 Monomeric and dimeric antibody-fragment fusion proteins

Publications (2)

Publication Number Publication Date
KR950700419A true KR950700419A (ko) 1995-01-16
KR100254759B1 KR100254759B1 (ko) 2000-05-01

Family

ID=8209260

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702517A KR100254759B1 (ko) 1992-01-23 1993-01-15 단량체 및 이량체 항체-단편 융합 단백질

Country Status (16)

Country Link
US (1) US5910573A (ko)
EP (1) EP0654085B1 (ko)
JP (2) JP3490437B2 (ko)
KR (1) KR100254759B1 (ko)
AT (1) ATE151113T1 (ko)
AU (1) AU676150B2 (ko)
CA (1) CA2128511C (ko)
CZ (1) CZ287296B6 (ko)
DE (1) DE69309472T2 (ko)
DK (1) DK0654085T3 (ko)
ES (1) ES2102007T3 (ko)
GR (1) GR3023860T3 (ko)
HU (1) HU215180B (ko)
NO (1) NO942750L (ko)
RU (1) RU2128709C1 (ko)
WO (1) WO1993015210A1 (ko)

Families Citing this family (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416738B1 (en) 1973-12-07 2002-07-09 Neorx Corporation Pretargeting methods and compounds
US6075010A (en) * 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
EP0625200B1 (en) * 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5911969A (en) 1992-06-09 1999-06-15 Neorx Corporation Pretargeting protocols for enhanced localization of active agents to target sites
US6358490B2 (en) 1992-06-09 2002-03-19 Neorx Corporation Three-step pretargeting methods and compounds
US6329507B1 (en) * 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
EP0743956A4 (en) * 1993-12-07 1999-03-24 Neorx Corp Warping and averaging procedures
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US20050214309A1 (en) * 1994-03-18 2005-09-29 Hinrichs Steven H Methods and compositions for modulating transcription factor activity
SE9401460D0 (sv) * 1994-04-28 1994-04-28 Ferring Ab Antigen/antibody specificity exhanger
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6040137A (en) * 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
EP0787185A2 (en) 1994-10-20 1997-08-06 MorphoSys AG Targeted hetero-association of recombinant proteins to multi-functional complexes
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
CA2222055A1 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
GB9718358D0 (en) * 1997-08-30 1997-11-05 Univ Leeds Chemical modification
US7105307B2 (en) 1997-08-30 2006-09-12 Cyclacel, Ltd. Compositions and methods for screening for modulators of enzymatic activity
DE69829995T2 (de) * 1997-12-01 2006-02-23 Fang, Fang, San Diego Multivalente rekombinante antikörper zur behandlung von hrv infektionen
US6204537B1 (en) 1998-10-01 2001-03-20 Micron Technology, Inc. ESD protection scheme
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US20030143234A1 (en) * 1999-08-20 2003-07-31 Wenyuan Shi Anti-microbial targeting chimeric pharmaceutical
US7569542B2 (en) 1999-08-20 2009-08-04 The Regents Of The University Of California Anti-microbial targeting chimeric pharmaceutical
DE60233509D1 (de) 2001-06-20 2009-10-08 Fibron Ltd Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
DE10133071A1 (de) * 2001-07-07 2003-03-06 Alexander Cherkasky Antigene, Rezeptoren, Liganden oder ihre Regionen kombiniert mit proteolytischer Aktivität
WO2003062370A2 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
WO2003018749A2 (en) * 2001-08-22 2003-03-06 Shengfeng Li Compositions and methods for generating antigen-binding units
US7175983B2 (en) * 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US7318926B2 (en) 2003-02-06 2008-01-15 Tripep Ab Glycosylated specificity exchangers
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2004238263A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
EP1624891B2 (en) * 2003-05-06 2013-04-10 Biogen Idec Hemophilia Inc. Clotting factor-fc chimeric proteins to treat hemophilia
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8551480B2 (en) * 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US7875598B2 (en) * 2004-03-04 2011-01-25 The Regents Of The University Of California Compositions useful for the treatment of microbial infections
EP2578226B1 (en) * 2004-08-23 2017-10-25 Yeda Research And Development Co., Ltd. Peptide for treating amyotrophic lateral sclerosis
CA2595398A1 (en) * 2004-11-04 2006-05-11 Fibron Limited Treatment of b-cell malignancies
US20120276100A1 (en) * 2005-04-06 2012-11-01 Ibc Pharmaceuticals, Inc. Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity
WO2006117782A2 (en) 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
US7989219B2 (en) 2005-05-31 2011-08-02 Canon Kabushiki Kaisha Bispecific capturing molecule
KR100832773B1 (ko) 2005-11-18 2008-05-27 주식회사 아이지세라피 기능성 Fv 항체 절편 제조 방법
JP2009529917A (ja) 2006-03-22 2009-08-27 ヴァイラル ロジック システムズ テクノロジー コーポレーション 標的ポリペプチドの同定方法および免疫学的疾患の治療のためのその使用
LT2004683T (lt) * 2006-03-24 2016-10-10 Biogen Hemophilia Inc. Pc5, kaip faktoriaus ix pro-peptidą apdorojantis fermentas
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US20080131431A1 (en) * 2006-05-15 2008-06-05 Viral Logic Systems Technology Corp. CD47 related compositions and methods for treating immunological diseases and disorders
WO2007144893A2 (en) * 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
AU2007292221B2 (en) 2006-09-06 2013-08-29 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof
EP2072527A1 (en) * 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
US9834600B2 (en) 2008-03-28 2017-12-05 Glaxosmithkline Llc Methods of treatment of eosinophilic bronchitis with an anti-IL-5 antibody
EP2324061B1 (en) 2008-09-03 2017-04-12 F. Hoffmann-La Roche AG Multispecific antibodies
TWI513466B (zh) * 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
BR112013025031A2 (pt) 2011-03-30 2017-08-01 Boehringer Ingelheim Int antídotos anticoagulantes
EP2715350B1 (en) 2011-05-23 2017-09-27 Yeda Research and Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US10036747B2 (en) * 2011-11-22 2018-07-31 University Of Maryland, Baltimore Lambodies with high affinity and selectivity for glycans and uses therefor
CN104159923B (zh) 2012-01-13 2018-01-23 乌利班-马克西姆利安大学 双抗原诱导的双功能互补作用
WO2013150518A1 (en) 2012-04-01 2013-10-10 Rappaport Family Institute For Research In The Medical Sciences Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
UY35463A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix.
JP6543626B2 (ja) 2013-07-29 2019-07-10 ブルーバード バイオ, インコーポレイテッド 多部分シグナル伝達タンパク質およびその使用
US9243294B2 (en) 2013-09-30 2016-01-26 Hadasit Medical Research Services And Development Ltd. Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
US10081679B2 (en) 2013-11-25 2018-09-25 Ccam Biotherapeutics Ltd. Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015229103C9 (en) 2014-03-14 2020-11-26 Immutep S.A.S Antibody molecules to LAG-3 and uses thereof
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
WO2015145449A2 (en) 2014-03-27 2015-10-01 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
CR20160534A (es) 2014-04-27 2017-04-25 Ccam Biotherapeutics Ltd Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
JP2016002009A (ja) * 2014-06-13 2016-01-12 国立大学法人名古屋大学 タグ付抗体
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
SG11201700476VA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
DK3183268T3 (da) 2014-08-19 2020-05-11 Univ Pennsylvania Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
CN114621969A (zh) 2014-09-17 2022-06-14 诺华股份有限公司 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對pd-l1之抗體分子及其用途
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
WO2016157195A1 (en) 2015-04-01 2016-10-06 Hadasit Medical Research Services And Development Ltd. Inhibitors of neuroligin 4 - neurexin 1-beta protein-protein interaction for treatment of liver disorders
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
ES2924071T3 (es) 2015-09-02 2022-10-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT)
US11161912B2 (en) 2015-10-13 2021-11-02 Technion Research & Development Foundation Limited Heparanase-neutralizing monoclonal antibodies
RU2018125603A (ru) 2015-12-17 2020-01-21 Новартис Аг Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения
US20180371093A1 (en) 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
EP3405492B1 (en) 2016-01-21 2020-10-21 Novartis AG Multispecific molecules targeting cll-1
EP4043492A1 (en) 2016-03-01 2022-08-17 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
SG11201809041TA (en) 2016-04-15 2018-11-29 Novartis Ag Compositions and methods for selective protein expression
GB201609235D0 (en) 2016-05-25 2016-07-06 Univ Cape Town Production of a horseradish peroxidase-IGG fusion protein
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
JP7219376B2 (ja) 2016-07-15 2023-02-08 ノバルティス アーゲー キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防
KR20190034588A (ko) 2016-07-28 2019-04-02 노파르티스 아게 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
KR20190036551A (ko) 2016-08-01 2019-04-04 노파르티스 아게 Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
US10525083B2 (en) 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
WO2018140725A1 (en) 2017-01-26 2018-08-02 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
JP7295038B2 (ja) 2017-06-06 2023-06-20 グラクソスミスクライン エルエルシー 小児患者のための生物薬剤組成物及び方法
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CN110785187B (zh) 2017-06-22 2024-04-05 诺华股份有限公司 针对cd73的抗体分子及其用途
US20200223924A1 (en) 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
KR20200031659A (ko) 2017-07-20 2020-03-24 노파르티스 아게 항-lag-3 항체의 투여 요법 및 그의 용도
KR20200089286A (ko) 2017-11-16 2020-07-24 노파르티스 아게 조합 요법
JP7431735B2 (ja) 2017-12-14 2024-02-15 2セブンティ バイオ インコーポレイテッド Daricインターロイキン受容体
JP7403455B2 (ja) * 2017-12-22 2023-12-22 ハンミ ファーマシューティカル カンパニー リミテッド 新規な構造を有する治療学的酵素融合タンパク質及びその用途
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
AU2019264965A1 (en) 2018-05-09 2020-11-19 Nectin Therapeutics Ltd. Antibodies specific to human Nectin4
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
AU2019272575A1 (en) 2018-05-21 2020-12-10 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by NK cells
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
CU20200089A7 (es) 2018-06-01 2021-07-02 Novartis Ag Moléculas de unión contra bcma
SG11202011830SA (en) 2018-06-13 2020-12-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
CA3104295A1 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
WO2020128898A1 (en) 2018-12-20 2020-06-25 Novartis Ag Pharmaceutical combinations
CN113271945A (zh) 2018-12-20 2021-08-17 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
CN113301954A (zh) 2019-01-13 2021-08-24 耶路撒冷希伯来大学伊森姆研究发展有限公司 特异性针对人类连接蛋白-2的抗体
EA202192029A1 (ru) 2019-02-15 2021-10-27 Новартис Аг Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения
KR20210129671A (ko) 2019-02-15 2021-10-28 노파르티스 아게 3-(1-옥소-5-(피페리딘-4-일)이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
EP3927371A1 (en) 2019-02-22 2021-12-29 Novartis AG Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
AU2020253833A1 (en) 2019-03-29 2021-10-28 Atarga, Llc Anti FGF23 antibody
KR20220004751A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
JOP20210309A1 (ar) 2019-05-21 2023-01-30 Novartis Ag جزيئات ربط بـ cd19 واستخدامتها
AU2020279224A1 (en) 2019-05-21 2021-12-16 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
US20210040197A1 (en) 2019-08-08 2021-02-11 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
BR112022007179A2 (pt) 2019-10-21 2022-08-23 Novartis Ag Inibidores de tim-3 e usos dos mesmos
AU2020370086A1 (en) 2019-10-21 2022-05-19 Novartis Ag Combination therapies with venetoclax and TIM-3 inhibitors
JP2022553830A (ja) 2019-11-05 2022-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド N末端scFv多重特異性結合分子
AR120566A1 (es) 2019-11-26 2022-02-23 Novartis Ag Receptores de antígeno quiméricos y sus usos
EP4076660A1 (en) 2019-12-20 2022-10-26 Novartis AG Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
US20210222244A1 (en) 2020-01-17 2021-07-22 Becton, Dickinson And Company Methods and compositions for single cell secretomics
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
CN115397460A (zh) 2020-02-27 2022-11-25 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
EP4126241A1 (en) 2020-03-27 2023-02-08 Novartis AG Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
KR20220164787A (ko) 2020-04-06 2022-12-13 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 암 및 감염의 치료를 위한 NKp46에 대한 항체 및 이의 작제물
WO2021220215A1 (en) 2020-05-01 2021-11-04 Novartis Ag Engineered immunoglobulins
US11673930B2 (en) 2020-05-12 2023-06-13 Regeneran Pharmaceuticals, Inc. IL10 agonists and methods of use thereof
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
EP4182025A1 (en) 2020-07-16 2023-05-24 Novartis AG Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022044010A1 (en) 2020-08-26 2022-03-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag CD19 binding molecules and their uses
US20240002509A1 (en) 2020-11-06 2024-01-04 Novartis Ag ANTIBODY Fc VARIANTS
CA3199839A1 (en) 2020-11-06 2022-05-12 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
JP2023549504A (ja) 2020-11-13 2023-11-27 ノバルティス アーゲー キメラ抗原受容体(car)発現細胞との組合せ療法
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
JP2024507124A (ja) 2021-02-11 2024-02-16 ネクチン セラピューティクス リミテッド Cd112rに対する抗体およびその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4334353A1 (en) 2021-05-04 2024-03-13 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
KR20240023123A (ko) 2021-06-22 2024-02-20 노파르티스 아게 화농성 한선염의 치료에 사용하기 위한 이중특이적 항체
WO2023004282A2 (en) 2021-07-19 2023-01-26 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
EP4387988A2 (en) 2021-08-16 2024-06-26 Regeneron Pharmaceuticals, Inc. Novel il27 receptor agonists and methods of use thereof
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023073599A1 (en) 2021-10-28 2023-05-04 Novartis Ag Engineered fc variants
WO2023086812A1 (en) 2021-11-11 2023-05-19 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023105528A1 (en) 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
US20230383010A1 (en) 2022-02-07 2023-11-30 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
WO2023148707A1 (en) 2022-02-07 2023-08-10 Yeda Research And Development Co. Ltd. Humanized anti quiescin suefhydrye oxidase 1 (qsox1) antibodies and uses thereof
TW202400658A (zh) 2022-04-26 2024-01-01 瑞士商諾華公司 靶向il—13和il—18的多特異性抗體
WO2023220647A1 (en) 2022-05-11 2023-11-16 Regeneron Pharmaceuticals, Inc. Multispecific binding molecule proproteins and uses thereof
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20230382969A1 (en) 2022-05-27 2023-11-30 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
WO2023235848A1 (en) 2022-06-04 2023-12-07 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024100663A1 (en) 2022-11-10 2024-05-16 Famewave Ltd. Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities
WO2024130175A2 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind to aav particles and uses
WO2024138191A1 (en) 2022-12-23 2024-06-27 Regeneron Pharmaceuticals, Inc. Ace2 fusion proteins and uses thereof
WO2024151978A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1993007286A1 (en) * 1991-09-30 1993-04-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Recombinant immunotoxins
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers

Also Published As

Publication number Publication date
AU3410093A (en) 1993-09-01
US5910573A (en) 1999-06-08
RU94045249A (ru) 1996-05-27
HUT68798A (en) 1995-07-28
CA2128511C (en) 2006-11-07
HU9402167D0 (en) 1994-10-28
DE69309472T2 (de) 1997-10-23
EP0654085B1 (en) 1997-04-02
CA2128511A1 (en) 1993-08-05
RU2128709C1 (ru) 1999-04-10
ES2102007T3 (es) 1997-07-16
EP0654085A1 (en) 1995-05-24
HU215180B (hu) 1998-10-28
JP3490437B2 (ja) 2004-01-26
JP2004041221A (ja) 2004-02-12
JPH07503366A (ja) 1995-04-13
WO1993015210A1 (en) 1993-08-05
KR100254759B1 (ko) 2000-05-01
NO942750L (no) 1994-09-13
CZ287296B6 (en) 2000-10-11
GR3023860T3 (en) 1997-09-30
DE69309472D1 (de) 1997-05-07
DK0654085T3 (da) 1997-09-22
AU676150B2 (en) 1997-03-06
CZ175794A3 (en) 1994-12-15
ATE151113T1 (de) 1997-04-15
NO942750D0 (no) 1994-07-22

Similar Documents

Publication Publication Date Title
KR950700419A (ko) 단량체 및 이량체 항체-단편 융합 단백질(monomeric and dimeric antibody-fragment fusion proteins)
CA1341411C (en) Method for producing fv fragments in eukaryotic cells
Wu et al. Functional production and characterization of a fibrin-specific single-chain antibody fragment from Bacillus subtilis: effects of molecular chaperones and a wall-bound protease on antibody fragment production
DE69232604T2 (de) Antikörperkonstrukte
EP0640130B1 (en) Chimeric multivalent protein analogues and methods of use thereof
JP3280376B2 (ja) 多価抗原結合性蛋白質
Jiang et al. Expression of Fab fragment of catalytic antibody 6D9 in an Escherichia coli in vitro coupled transcription/translation system
Yarmush et al. Immunoadsorption: strategies for antigen elution and production of reusable adsorbents
JP3043407B2 (ja) 完全合成アフィニティ試薬
JPH07507682A (ja) Lプロテインに由来する免疫グロブリン結合性タンパク質およびその用途
Humphreys et al. Formation of dimeric Fabs in Escherichia coli: effect of hinge size and isotype, presence of interchain disulphide bond, Fab′ expression levels, tail piece sequences and growth conditions
Lee et al. Covalent and oriented surface immobilization of antibody using photoactivatable antibody Fc-binding protein expressed in Escherichia coli
Adlersberg The immunoglobulin hinge (interdomain) region
US5965405A (en) Method for producing Fv fragments in eukaryotic cells
Anand et al. Synthesis and expression in Escherichia coli of cistronic DNA encoding an antibody fragment specific for a Salmonella serotype B O-antigen
Rajagopal et al. A form of anti-Tac (Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs.
Pedrazzi et al. Affinity and folding properties both influence the selection of antibodies with the selectively infective phage (SIP) methodology
Dieringer et al. Structural studies of human basement-membrane collagen with the use of a monoclonal antibody
US20080280346A1 (en) System For the Production of Dimeric Proteins Based on the Transport System of Hemolysin of Escherichia Coli
Hass et al. Preparation of synthetic polypeptide domains of carcinoembryonic antigen and their use in epitope mapping
US6652863B1 (en) Method of reducing the immunogenicity of compounds
Muesing et al. High-level expression in Escherichia coli of calcium-binding domains of an embryonic sea urchin protein
CA2157387C (en) Method and compositions for recombinant osteogenic protein production
US11414454B2 (en) Compositions, methods, and systems for affinity-based protein identification and purification
Fursova et al. Refolding of scFv mini-antibodies using size-exclusion chromatography via arginine solution layer

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120203

Year of fee payment: 13

EXPY Expiration of term